Results 91 to 100 of about 2,243,647 (283)
Cancer & MetabolismBackground Lactate dehydrogenase A (LDHA) can regulate tumorigenesis and cancer progression. Nevertheless, whether the regulation of LDHA is involved in the development of gemcitabine resistance in PDAC has not yet been fully elucidated.
Tung-Wei Hsu +11 more
doaj +1 more source
Advanced Science, EarlyView.This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu +10 more
wiley +1 more source
Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment
Advanced Science, EarlyView.This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo +15 more
wiley +1 more source
Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer
JOP : Journal of the pancreas, 2010 Context Pancreatic cancer is noteworthy in that the number of patients dying from the disease is roughly equal to the number diagnosed. For more than a decade, gemcitabine has constituted the standard of care for the palliative treatment of the majority of patients who present with metastatic or relapsed disease, although the survival gains are limited.
Ioannis, Gounaris +2 more
openaire +2 more sources
Molecular mechanisms of acquired gemcitabine resistance in pancreatic cancer
, 2014 Indiana University-Purdue University (IUPUI)Most pancreatic cancer patients receiving gemcitabine chemotherapy eventually develop resistance to gemcitabine.
Qin, Li
core +1 more source
Advanced Science, EarlyView.Pasta is a transcriptomic aging clock built on an age‐shift learning framework and trained on 17 000 samples across 21 datasets. It accurately predicts relative biological age across tissues, platforms, and species, captures stemness‐to‐senescence transitions, and identifies age‐modulatory perturbations.
Jérôme Salignon +6 more
wiley +1 more source
Targeting ketone body metabolism in mitigating gemcitabine resistance. [PDF]
JCI InsightChemotherapy is often combined with surgery for muscle invasive and nonmuscle invasive bladder cancer (BCa). However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark in cancer chemoresistance.
Rohena-Rivera K +9 more
europepmc +3 more sources
Advanced Science, EarlyView.A schematic model summarizing GNA15's mechanism in mediating macrophage M2 polarization and Gemcitabine resistance. ABSTRACT The complexity of pancreatic ductal adenocarcinoma (PDAC) progression, coupled with the lack of effective immunotherapy, underscores the imperative to deepen our understanding of its mechanisms and identify suitable immune ...
Weihui Guo +8 more
wiley +1 more source
Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]
, 2015 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Wang, X +23 more
core +1 more source
Advanced Science, EarlyView.This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu +9 more
wiley +1 more source